Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
Gespeichert in:
| Veröffentlicht in: | The Journal of clinical investigation 2000-01, Vol.105 (1), p.3-7 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7 |
|---|---|
| container_issue | 1 |
| container_start_page | 3 |
| container_title | The Journal of clinical investigation |
| container_volume | 105 |
| creator | Druker, B J Lydon, N B |
| description | |
| doi_str_mv | 10.1172/jci9083 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_382593</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70801829</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-6fc84ca5df295789b12e86bb1c3015e838917f6bc8e6f2e881a555da2c9b77b33</originalsourceid><addsrcrecordid>eNpVUT1PwzAQ9QCipSD-AfIEU8FO4sQeGFDFR1ElFpgt2zm3bhO72Gml_ntStUJlON1w7717dw-hG0oeKK2yx6VxgvD8DA0JyehYVDkfoMuUloTQomDFBRpQUlLBWTFEbgYpBZ9wAyp6qLGNocXdAnANW2jCugXf4WCx8ljpBne7GJLzgFfOqwTY-YXTrgsR277MIgbvDG53PXUOPmz2wpsVtE5doXOrmgTXxz5C368vX5P38ezzbTp5no1NUfJuXFrDC6NYbTPBKi40zYCXWlOTE8qA51zQypbacChtP-JUMcZqlRmhq0rn-Qg9HXTXG91CbXr_UTVyHV2r4k4G5eT_iXcLOQ9bmfOMiT3_7siP4WcDqZOtSwaaRnno75EV4YTyTPTA-wPQ9C9JEezfDkrkPgn5MZnuk-iRt6eWTnCHGPJfRJeJEQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70801829</pqid></control><display><type>article</type><title>Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Druker, B J ; Lydon, N B</creator><creatorcontrib>Druker, B J ; Lydon, N B</creatorcontrib><identifier>ISSN: 0021-9738</identifier><identifier>DOI: 10.1172/jci9083</identifier><identifier>PMID: 10619854</identifier><language>eng</language><publisher>United States: American Society for Clinical Investigation</publisher><subject>Antineoplastic Agents - therapeutic use ; Benzamides ; Binding Sites ; Drug Design ; Enzyme Inhibitors - therapeutic use ; Humans ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Piperazines - pharmacology ; Piperazines - therapeutic use ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Proto-Oncogene Proteins c-abl - antagonists & inhibitors ; Proto-Oncogene Proteins c-abl - chemistry ; Pyrimidines - pharmacology ; Pyrimidines - therapeutic use</subject><ispartof>The Journal of clinical investigation, 2000-01, Vol.105 (1), p.3-7</ispartof><rights>Copyright © 2000, American Society for Clinical Investigation 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-6fc84ca5df295789b12e86bb1c3015e838917f6bc8e6f2e881a555da2c9b77b33</citedby><cites>FETCH-LOGICAL-c468t-6fc84ca5df295789b12e86bb1c3015e838917f6bc8e6f2e881a555da2c9b77b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC382593/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC382593/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10619854$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Druker, B J</creatorcontrib><creatorcontrib>Lydon, N B</creatorcontrib><title>Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides</subject><subject>Binding Sites</subject><subject>Drug Design</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Piperazines - pharmacology</subject><subject>Piperazines - therapeutic use</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Proto-Oncogene Proteins c-abl - antagonists & inhibitors</subject><subject>Proto-Oncogene Proteins c-abl - chemistry</subject><subject>Pyrimidines - pharmacology</subject><subject>Pyrimidines - therapeutic use</subject><issn>0021-9738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUT1PwzAQ9QCipSD-AfIEU8FO4sQeGFDFR1ElFpgt2zm3bhO72Gml_ntStUJlON1w7717dw-hG0oeKK2yx6VxgvD8DA0JyehYVDkfoMuUloTQomDFBRpQUlLBWTFEbgYpBZ9wAyp6qLGNocXdAnANW2jCugXf4WCx8ljpBne7GJLzgFfOqwTY-YXTrgsR277MIgbvDG53PXUOPmz2wpsVtE5doXOrmgTXxz5C368vX5P38ezzbTp5no1NUfJuXFrDC6NYbTPBKi40zYCXWlOTE8qA51zQypbacChtP-JUMcZqlRmhq0rn-Qg9HXTXG91CbXr_UTVyHV2r4k4G5eT_iXcLOQ9bmfOMiT3_7siP4WcDqZOtSwaaRnno75EV4YTyTPTA-wPQ9C9JEezfDkrkPgn5MZnuk-iRt6eWTnCHGPJfRJeJEQ</recordid><startdate>200001</startdate><enddate>200001</enddate><creator>Druker, B J</creator><creator>Lydon, N B</creator><general>American Society for Clinical Investigation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200001</creationdate><title>Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia</title><author>Druker, B J ; Lydon, N B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-6fc84ca5df295789b12e86bb1c3015e838917f6bc8e6f2e881a555da2c9b77b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides</topic><topic>Binding Sites</topic><topic>Drug Design</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Piperazines - pharmacology</topic><topic>Piperazines - therapeutic use</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Proto-Oncogene Proteins c-abl - antagonists & inhibitors</topic><topic>Proto-Oncogene Proteins c-abl - chemistry</topic><topic>Pyrimidines - pharmacology</topic><topic>Pyrimidines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Druker, B J</creatorcontrib><creatorcontrib>Lydon, N B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Druker, B J</au><au>Lydon, N B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>2000-01</date><risdate>2000</risdate><volume>105</volume><issue>1</issue><spage>3</spage><epage>7</epage><pages>3-7</pages><issn>0021-9738</issn><cop>United States</cop><pub>American Society for Clinical Investigation</pub><pmid>10619854</pmid><doi>10.1172/jci9083</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9738 |
| ispartof | The Journal of clinical investigation, 2000-01, Vol.105 (1), p.3-7 |
| issn | 0021-9738 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_382593 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antineoplastic Agents - therapeutic use Benzamides Binding Sites Drug Design Enzyme Inhibitors - therapeutic use Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Piperazines - pharmacology Piperazines - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Proto-Oncogene Proteins c-abl - antagonists & inhibitors Proto-Oncogene Proteins c-abl - chemistry Pyrimidines - pharmacology Pyrimidines - therapeutic use |
| title | Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T21%3A10%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lessons%20learned%20from%20the%20development%20of%20an%20abl%20tyrosine%20kinase%20inhibitor%20for%20chronic%20myelogenous%20leukemia&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Druker,%20B%20J&rft.date=2000-01&rft.volume=105&rft.issue=1&rft.spage=3&rft.epage=7&rft.pages=3-7&rft.issn=0021-9738&rft_id=info:doi/10.1172/jci9083&rft_dat=%3Cproquest_pubme%3E70801829%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70801829&rft_id=info:pmid/10619854&rfr_iscdi=true |